Angela M. DeMichele, MD
Although CDK4/6 inhibitors are remaking the treatment landscape for patients with estrogen receptor (ER)–positive metastatic breast cancer, questions about optimal sequencing and strategies for attacking resistance and progression remain unsettled, according to Angela DeMichele, MD, MSCE.
Table. CDK 4/6 Inhibitor Efficacy by Line of Therapy1
In MONARCH 2, 669 women with HR-positive, HER2-negative advanced breast cancer resistant to endocrine therapy were assigned to abemaciclib plus fulvestrant or to placebo and fulvestrant. At a median follow-up of 19.5 months, the median PFS with the combination was 16.4 months compared to 9.3 months with placebo (hazard ratio, 0.553; P
<.001). The objective response rates were 48.1% vs 21.3%, respectively.4
... to read the full story